Browse / Semaglutide

Semaglutide

GLP-1 receptor agonist

Injectable Start 0.25 mg weekly, titrate monthly to target dose Once weekly VERY LARGE

Overview

What is Semaglutide?

Semaglutide is a long-acting GLP-1 receptor agonist. Approved drug products are distinct from research-use lyophilized vials sold for laboratory work. All catalog material is for laboratory research use only.

Key Benefits

FDA-approved molecule in licensed products, once-weekly convenience, substantial clinical-trial weight-change and glycemic data, long plasma half-life versus native GLP-1.

Mechanism of Action

GLP-1R activation increases glucose-dependent insulin secretion, slows gastric emptying, and reduces appetite signaling in hypothalamic circuits — mechanisms mapped in both animal and clinical literature.

Quick Start Guide

Typical Dose Start 0.25 mg weekly, titrate monthly to target dose
How Often Once weekly, same day each week
Where to Inject Abdomen, thigh, or upper arm (rotate weekly)
Injection Timing Any time of day, with or without food
Effects Timeline Appetite: 1–2 weeks, Weight loss: 4–8 weeks, Full effects: 3–4 months
Storage Refrigerate before first use, then refrigerate or room temp up to 28 days
Cycle Length Ongoing treatment as prescribed
Break Between Not applicable — continuous therapy

Molecular Information

Weight: 4113.58 g/mol
Length: 31 amino acids (acylated analogue)
Type: GLP-1 receptor agonist
Formula: C187H291N45O59

Amino Acid Sequence GLP-1(7-37) analog with non-natural residues and fatty-acid side chain; see CoA for full sequence.

Research directions

Metabolic disease literature Very large

Glycemia and weight endpoints in licensed-drug trials

Pharmacokinetics

Peak 1–3 days (weekly clinical forms)

Half-life ~7 days

Cleared weeks

Clinical PK of approved presentations.

Literature

STEP 1 — 2021 · Clinical. Weekly semaglutide in obesity.